TickerFacts.

Viatris Inc (VTRS): Cost of Revenue

Annual figures by period end, from SEC filings.

$9.29B
Year ended 2025-12-31
$9.60B
Trailing 12 months to 2026-06-30
-1.7%
3-year compound annual growth
+2.6%
5-year compound annual growth
$12.31B2018-12-31: $7.43B2019-12-31: $7.60B2020-12-31: $8.15B2021-12-31: $12.31B2022-12-31: $9.77B2023-12-31: $8.99B2024-12-31: $9.12B2025-12-31: $9.29B$9.29B
2018-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$9.29B+1.9%2026-02-26, From 2025-01-01
2024-12-31$9.12B+1.4%2026-02-26, From 2024-01-01
2023-12-31$8.99B-8.0%2026-02-26, From 2023-01-01
2022-12-31$9.77B-20.7%2025-02-27, From 2022-01-01
2021-12-31$12.31B+51.1%2024-02-28, From 2021-01-01
2020-12-31$8.15B+7.2%2023-02-27, From 2020-01-01
2019-12-31$7.60B+2.3%2022-02-28, From 2019-01-01
2018-12-31$7.43Bn/a2021-03-01, From 2018-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Viatris Inc (VTRS)2025-12-31$9.29B+1.9%
Vertex Pharmaceuticals Inc (VRTX)2025-12-31$1.65B+7.9%
Teva Pharmaceutical Industries Ltd (TEVA)2025-12-31$8.32B-1.9%
Zoetis Inc. (ZTS)2025-12-31$2.67B-1.9%
Organon & Co. (OGN)2025-12-31$2.90B+8.0%
Elanco Animal Health Inc (ELAN)2025-12-31$2.12B+5.9%
Abbott Laboratories (ABT)2025-12-31$19.32B+3.3%
Perrigo Co PLC (PRGO)2025-12-31$2.76B-2.5%
Bristol Myers Squibb Co (BMY)2025-12-31$13.94B-0.2%

Compare VTRS, VRTX, TEVA, ZTS side by side · Screen every company in Pharmaceutical Preparations ↗